Workflow
昭衍新药(603127) - 2019 Q3 - 季度财报
2019-10-30 16:00

Financial Performance - Net profit attributable to shareholders rose by 33.66% to CNY 76,483,113.45 year-to-date[6] - Operating revenue for the first nine months increased by 42.95% to CNY 348,455,173.43 compared to the same period last year[6] - Total operating revenue for Q3 2019 reached ¥147,591,290.64, a 36% increase from ¥108,635,875.59 in Q3 2018[25] - Net profit for Q3 2019 was ¥36,082,118.04, compared to ¥34,758,065.96 in Q3 2018, reflecting a 4% increase[28] - The total comprehensive income attributable to the parent company for Q3 2019 was CNY 37,389,315.57, compared to CNY 36,212,602.06 in Q3 2018, indicating a slight increase of approximately 3.2%[29] Assets and Liabilities - Total assets increased by 16.58% to CNY 1,330,611,638.65 compared to the end of the previous year[6] - Total liabilities rose to ¥615,970,500.76 from ¥489,888,909.10, marking an increase of around 25.8%[21] - Current assets totaled ¥811,871,659.77, compared to ¥689,899,815.86, reflecting an increase of about 17.7%[20] - Non-current assets amounted to ¥518,739,978.88, up from ¥451,509,885.16, indicating a growth of approximately 14.9%[20] - Total liabilities as of Q3 2019 were ¥276,633,197.29, up from ¥239,915,890.76 in the previous year[25] Cash Flow - Net cash flow from operating activities decreased by 20.11% to CNY 97,256,435.71 year-to-date[6] - The company's cash flow from operating activities for the first nine months of 2019 was CNY 414,445,908.96, compared to CNY 349,546,851.86 in the same period of 2018, representing a growth of approximately 18.5%[33] - The net cash flow from operating activities for Q3 2019 was ¥97,256,435.71, a decrease of 20% compared to ¥121,738,047.54 in Q3 2018[34] - Total cash inflow from investment activities was ¥879,340,955.42, significantly higher than ¥455,265,824.53 in the same quarter last year, marking an increase of approximately 93%[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,600[10] - The largest shareholder, Feng Yuxia, holds 28.38% of the shares, with 19,865,952 shares pledged[10] - The total number of shareholders with priority shares is not applicable, indicating no priority shares were issued[12] Expenses - Research and development expenses increased by 51.50%, amounting to RMB 26,744,387.51, compared to RMB 18,188,639.43 in the previous year[15] - The company reported a significant increase in sales expenses by 90.44%, totaling RMB 8,055,995.42, compared to RMB 4,230,193.92 in the previous year[15] - Total operating costs for Q3 2019 were ¥107,617,425.80, up 44% from ¥74,695,943.92 in Q3 2018[27] Equity and Earnings - The weighted average return on equity increased by 1.38 percentage points to 11.26%[6] - Basic and diluted earnings per share decreased by 6.00% to CNY 0.47[7] - Earnings per share for Q3 2019 were ¥0.22, compared to ¥0.21 in Q3 2018[28] - Shareholders' equity increased to ¥714,641,137.89, compared to ¥651,520,791.92, showing a growth of about 9.7%[21] Government Support - The company received government subsidies amounting to CNY 6,844,161.76 year-to-date, which are closely related to its normal business operations[8] Market Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[22]